1. HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia
- Author
-
Rainone, Michael, Behrendt, Carolyn E, Kasparian, Saro, Nguyen, Tina, Sedrak, Mina S, Lavasani, Sayeh, Stewart, Daphne B, Yuan, Yuan, Mortimer, Joanne E, Waisman, James R, Patel, Niki, and Pullarkat, Vinod
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Patient Safety ,Cancer ,Precision Medicine ,Women's Health ,Breast Cancer ,6.1 Pharmaceuticals ,Humans ,Female ,Breast Neoplasms ,Retrospective Studies ,Receptor ,ErbB-2 ,Maytansine ,Trastuzumab ,Ado-Trastuzumab Emtansine ,Immunoconjugates ,Thrombocytopenia ,HER2 positive breast cancer ,Trastuzumab deruxtecan ,Trastuzumab emtansine ,Asian ancestry ,Receptor ,erbB-2 ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundThrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1). A reported association of Asian ancestry with this event merits investigation to rule out potential confounding.MethodsSubjects in this retrospective cohort were female patients with HER2 positive breast cancer, of Asian or non-Hispanic White ancestry, who initiated T-DM1 or T-DXd from January 2017 through October 2021. Follow-up closed in January 2022. Primary endpoint was dose adjustment for thrombocytopenia. Competing endpoints were discontinuation of drug for other toxicity, disease progression, or for completion of prescribed cycles. The association between Asian ancestry and thrombocytopenia-related dose adjustment was tested at p
- Published
- 2023